venBio Global Strategic — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)Mark Bradley(Chief Development Officer)Kolbot By(SVP, Head of Technical Operations)Jack Danilkowicz(Chief Commercial Officer)Jörn Drappa(Chief Medical Officer)David M Goldstein(Chief Scientific Officer)
Board seatRichard Gaster· per SEC Form D · $259M raise · filed Mar 2024
Co-investorsForesite CapitalNextech InvestOrbiMedSamsara BioCapitalSR One Capital ManagementvenBio Partners+1 more
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.
BiotechHealthtechSouth San Francisco, US
Jonathan Wall(Executive Officer)Spencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)Benson Fong(Executive Officer)Rahul Kakkar(Director)Greg Bell(Executive Officer)
Board seatCorey GoodmanRichard Gaster· per SEC Form D · $56M raise · filed Feb 2024
Co-investorsAlpha Wave GlobalBioBritvenBio Partners
West Hills, US
Board seatYvonne Yamanaka· per SEC Form D · $141.8M raise · filed Apr 2024
Co-investorsDecheng CapitalNovartis Venture FundRMGP Biopharma Investment Fund
Axonis Therapeutics is a drug discovery company developing first-in-class therapies for currently incurable neurological disorders.
BiotechDeep TechHealthtechMedical DevicesBoston, US
Shane Hegarty(Executive Officer)Shane V. Hegarty(Chief Scientific Officer & Co-Founder)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Chief Executive Officer, President & Co-Founder)Jeff Imbaro(Chief Operating Officer)Tiasha Shafiq(Chief of Staff)
Co-investorsCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture PartnersIaso VenturesLumira VenturesPathway Bioventures+6 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.